ZA200506625B - 2-aminoethyl substituted pyrimidin-2-ones, cyclopropanes, pyrazolines, pyrimidines and benzothiazepines and their use as urotensin II and somottostatin 5 receptor ligands - Google Patents

2-aminoethyl substituted pyrimidin-2-ones, cyclopropanes, pyrazolines, pyrimidines and benzothiazepines and their use as urotensin II and somottostatin 5 receptor ligands Download PDF

Info

Publication number
ZA200506625B
ZA200506625B ZA200506625A ZA200506625A ZA200506625B ZA 200506625 B ZA200506625 B ZA 200506625B ZA 200506625 A ZA200506625 A ZA 200506625A ZA 200506625 A ZA200506625 A ZA 200506625A ZA 200506625 B ZA200506625 B ZA 200506625B
Authority
ZA
South Africa
Prior art keywords
compound
group
composition
substance
optionally substituted
Prior art date
Application number
ZA200506625A
Other languages
English (en)
Inventor
Roger Olsson
Original Assignee
Accadia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Accadia Pharmaceuticals Inc filed Critical Accadia Pharmaceuticals Inc
Publication of ZA200506625B publication Critical patent/ZA200506625B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/14Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
    • C07C225/16Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C225/18Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings the carbon skeleton containing also rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D281/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02Seven-membered rings
    • C07D281/04Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
ZA200506625A 2003-02-19 2005-08-18 2-aminoethyl substituted pyrimidin-2-ones, cyclopropanes, pyrazolines, pyrimidines and benzothiazepines and their use as urotensin II and somottostatin 5 receptor ligands ZA200506625B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44862903P 2003-02-19 2003-02-19

Publications (1)

Publication Number Publication Date
ZA200506625B true ZA200506625B (en) 2006-08-30

Family

ID=32908620

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200506625A ZA200506625B (en) 2003-02-19 2005-08-18 2-aminoethyl substituted pyrimidin-2-ones, cyclopropanes, pyrazolines, pyrimidines and benzothiazepines and their use as urotensin II and somottostatin 5 receptor ligands

Country Status (12)

Country Link
US (1) US20100029612A1 (zh)
EP (1) EP1638946A2 (zh)
JP (1) JP2006520328A (zh)
KR (1) KR20050100695A (zh)
CN (1) CN1751029A (zh)
AU (1) AU2004213000A1 (zh)
BR (1) BRPI0407651A (zh)
CA (1) CA2515706A1 (zh)
MX (1) MXPA05008802A (zh)
RU (1) RU2005129099A (zh)
WO (1) WO2004073642A2 (zh)
ZA (1) ZA200506625B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2970651B1 (fr) * 2011-01-25 2013-03-01 Ct Hospitalier Universitaire Rouen Urotensine ii et agonistes du recepteur de l'urotensine ii pour utilisation dans le traitement symptomatique du choc septique
JP6379805B2 (ja) * 2013-09-17 2018-08-29 株式会社リコー 情報処理プログラム、情報処理装置および情報処理システム

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2683742A (en) * 1951-02-23 1954-07-13 Searle & Co Nu, nu-disubstituted omega-arylmethoxy-omega-arylalkylamine derivatives
US2793212A (en) * 1953-12-09 1957-05-21 Lilly Co Eli Substituted benzamidopiperidinopropanes
US3096329A (en) * 1957-10-15 1963-07-02 Sterling Drug Inc Triazolo [b] pyridazines
GB1143703A (zh) * 1965-03-18
US3401166A (en) * 1966-08-01 1968-09-10 Squibb & Sons Inc Therapeutically active benzothiazines
US3880885A (en) * 1971-11-23 1975-04-29 Sandoz Ag Tertiary aminoethyl isochromans and isocoumarins
DE3243518A1 (de) * 1982-11-25 1984-05-30 Basf Ag, 6700 Ludwigshafen Substituierte 1-oxo-2-phenyl-2-(2-alkylaminoethyl)-1,2,3,4- tetrahydronaphthaline, ihre herstellung und verwendung
US5707798A (en) * 1993-07-13 1998-01-13 Novo Nordisk A/S Identification of ligands by selective amplification of cells transfected with receptors
US6605623B1 (en) * 1998-12-18 2003-08-12 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6511994B2 (en) * 2000-10-11 2003-01-28 Merck & Co., Inc. Modulators of CCR5 chemokine receptor activity

Also Published As

Publication number Publication date
BRPI0407651A (pt) 2006-02-21
AU2004213000A1 (en) 2004-09-02
CA2515706A1 (en) 2004-09-02
RU2005129099A (ru) 2006-04-20
KR20050100695A (ko) 2005-10-19
MXPA05008802A (es) 2005-10-18
JP2006520328A (ja) 2006-09-07
CN1751029A (zh) 2006-03-22
US20100029612A1 (en) 2010-02-04
WO2004073642A3 (en) 2005-03-17
WO2004073642A2 (en) 2004-09-02
EP1638946A2 (en) 2006-03-29

Similar Documents

Publication Publication Date Title
US6673799B1 (en) Cyanophenyl derivative
JP4536517B2 (ja) γ−セクレターゼ阻害剤としてのスルホンアミド、スルファメート及びスルファミド
CA2748251C (en) Bicyclic heterocyclic compound for use as a sensory neuron specific sodium channel inhibitor
JP4714686B2 (ja) 新規のγ−セクレターゼ阻害剤
US6127541A (en) Imidazoquinazoline derivatives
US8372844B2 (en) Piperazinyl-propyl-pyrazole derivatives as dopamine D4 receptor antagonists, and pharmaceutical compositions containing the same
US20060122229A1 (en) 4,5-diarylthiazole derivatives as cb-1 ligands
HU218945B (hu) Pirazolo-pirimidinon-származékok és a vegyületeket tartalmazó gyógyászati készítmények, eljárás a vegyületek és a készítmények előállítására
PT1438296E (pt) Derivados de 1h-imidazol possuindo actividade agonística cb1, antagonista parcial cb1 ou antagonista cb1
JP2006508092A (ja) γ−セクレターゼの阻害のための環状スルファミド
JP2005517655A (ja) Cb1アンタゴニストとしての5,6−ジアリール−ピラジン−2−アミド誘導体
CN102786525B (zh) N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用
TWI607003B (zh) 適用於治療對多巴胺d3受體調節有反應的病症之醯胺基環烷基化合物
EP4212522A1 (en) Compounds for suppressing egfr mutant cancer and pharmaceutical use thereof
EP1966146B1 (en) 4,5-dihydro- (1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators
EP3197876B1 (en) Novel chiral synthesis of n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines
EP1636221B1 (en) 3-Heterocyclyl-Azetidine compounds useful as NK1/NK2 receptors antagonists
KR20130046436A (ko) 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n''-다이아릴티오우레아 및 n,n''-다이아릴우레아, 이의 제조방법 및 이의 용도
IL296413A (en) gpr52 modulator compounds
JP3870298B2 (ja) アミド誘導体
JP4833832B2 (ja) ピラゾール化合物
JP2011515359A (ja) 治療用トリアゾールアミド誘導体
ZA200506625B (en) 2-aminoethyl substituted pyrimidin-2-ones, cyclopropanes, pyrazolines, pyrimidines and benzothiazepines and their use as urotensin II and somottostatin 5 receptor ligands
JP5944483B2 (ja) アダマンチル基を有するスルファミド誘導体及びこれの薬剤学的に許容可能な塩
CZ2004639A3 (cs) Deuterované pyrazolpyrimidinony a léčiva obsahující tyto sloučeniny